Cargando…
P874: LONG-TERM REMISSION AND SURVIVAL IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AFTER TREATMENT OF LCAR-B38M CAR-T – AT LEAST 5-YEAR FOLLOW-UP IN LEGEND-2
Autores principales: | MI, Jian‑qing, Zhao, Wan‑hong, Chen, Li‑juan, Fu, Weijun, Wang, Bai‑yan, Xu, Jie, Liu, Jie, Jin, Shi‑wei, Zhu, Han, Du, Juan, Jiang, Hua, Sun, Huabin, Jia, Yehui, Fan, Xiao‑hu, LI, Jian‑yong, Hou, Jian, Chen, Zhu, Zhang, Wang‑gang, He, Ai‑li, Chen, Sai‑juan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431000/ http://dx.doi.org/10.1097/01.HS9.0000970400.98418.89 |
Ejemplares similares
-
Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2)
por: Zhao, Wan-Hong, et al.
Publicado: (2022) -
Five-year remission without disease progression in a patient with relapsed/refractory multiple myeloma with extramedullary disease treated with LCAR-B38M chimeric antigen receptor T cells in the LEGEND-2 study: a case report
por: Wang, Bai-Yan, et al.
Publicado: (2022) -
A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma
por: Zhao, Wan-Hong, et al.
Publicado: (2018) -
DNA methylation mediated silencing of microRNA-874 is a promising diagnosis and prognostic marker in breast cancer
por: Zhang, Lei, et al.
Publicado: (2017) -
Single VHH-directed BCMA CAR-T cells cause remission of relapsed/refractory multiple myeloma
por: Han, Lu, et al.
Publicado: (2021)